Stem Cell Therapy for Back Pain and Degenerative Discs
Chronic low back pain from degenerative disc disease is a large and frustrating problem, and conventional options are genuinely limited. That combination is why stem cell treatment is heavily marketed for it.
The research here is more active than for most marketed indications — and still not enough to call this proven.
What the treatment involves
Mesenchymal stromal cells are injected directly into the affected intervertebral disc — an intradiscal injection — under fluoroscopic or CT guidance. The theory is that the cells reduce inflammation and may support the disc’s remaining cells.
Cost is typically $8,000–$20,000 in the US and $5,000–$12,000 in Mexico. Spinal injections cost more than joint injections, partly because imaging guidance is more involved.
What the research shows
Several systematic reviews have found that intradiscal MSC injection is associated with reductions in pain and disability scores. Those reviews consistently note the same limitations: small samples, few controlled trials, short follow-up, inconsistent outcome measures, and a high risk of bias.
More recently, the DREAM study — a double-blind, phase IIb randomised trial of intradiscal mesenchymal stromal cell therapy for low back pain due to moderate-to-advanced multilevel disc degeneration — has reported preliminary results. Properly controlled trials of this kind are what the field has been missing, and they are the results worth watching.
Where things currently stand: the signal is more encouraging than for most marketed indications, and the evidence is still not sufficient to establish benefit. Anyone telling you this is proven is ahead of the data.
An important caution about back pain specifically
Low back pain is the condition where placebo and natural-history effects are strongest across all of medicine. It fluctuates dramatically. Most acute episodes improve regardless of treatment. Invasive procedures produce large placebo responses — sham surgery trials in spine care have repeatedly matched real surgery.
Any uncontrolled report of improvement after a spinal injection must be read with that in mind. It is precisely why the controlled trials matter so much more here than the testimonials.
Risks specific to spinal injection
Beyond the general risks of stem cell treatment, intradiscal injection carries its own:
- Accelerated disc degeneration. Puncturing a disc can itself contribute to degeneration — documented with discography.
- Discitis. Infection of the disc space is uncommon but serious and difficult to treat.
- Nerve injury from needle placement.
- Increased pain, sometimes lasting weeks.
- Tumour formation. A spinal mass following stem cell injections at an unregulated clinic has been reported in the literature.
The spine is less forgiving than a knee. Who performs the injection, and under what imaging, matters more here than anywhere else.
What is better evidenced
For chronic low back pain, the treatments with the strongest support are unglamorous:
- Structured exercise therapy — the most consistently supported intervention
- Cognitive functional therapy and pain education — strong recent evidence
- Weight management and activity modification
- Targeted physical therapy
Guidelines generally recommend these before any injection-based procedure, and they are covered by insurance.
Questions for your clinic
- Which randomised controlled trial supports intradiscal cell therapy for my specific pathology?
- What imaging guidance is used, and who performs the injection?
- What is your rate of post-procedure discitis, and how do you screen for it?
- Has my diagnosis been confirmed as discogenic pain, and how?
- What is the total cost including any second session?
That fourth question matters more than it sounds. Much chronic back pain is not clearly discogenic, and treating a disc that is not the pain source cannot work regardless of what is injected.
Sources
- Intradiscal Mesenchymal Stromal Cell Therapy for Low Back Pain Due to Moderate-to-Advanced Multilevel Disc Degeneration: Preliminary Report of a Double-Blind, Phase IIB Randomised Clinical Trial (DREAM Study), 2025.
- Stem cell therapy for degenerative disc disease: a systematic review of preclinical evidence and clinical translation. North American Spine Society Journal, 2025.
- Mesenchymal stem cells for discogenic pain: systematic review and meta-analysis. Frontiers in Bioengineering and Biotechnology, 2023.
Not sure whether this is right for you?
Tell us about your condition and we will send you our free clinic-vetting checklist, an honest summary of the evidence for your situation, and — where they exist — free clinical trials you may be eligible for. Get matched with a vetted clinic
Medical disclaimer
This article is for general information and is not medical advice. We are not a healthcare provider and do not diagnose or treat any condition. Most stem cell treatments discussed here are not FDA approved for these uses, outcomes vary, and no result is guaranteed. Always speak with a licensed physician who knows your history. See our medical disclaimer and how we make money.